The European healthcare technology and medical technology sectors have transitioned into a period of disciplined industrial maturity. The speculative, venture-subsidised fragmentation of the early 2020s has given way to a transactional ecosystem where strategic value is defined by clinical utility, regulatory resilience, and technological defensibility. This maturation has driven a corresponding transformation in mergers and acquisitions advisory. This shift has reopened the

They are called Founder Bankers: former entrepreneurs and clinicians who built, scaled and exited their own healthcare technology ventures before transitioning into the advisory role. The model fuses deep operational pedigree with sophisticated investment banking methodology, offering what traditional finance cannot easily replicate, fluency in the lived experience of company-building, clinical pathway navigation and the psychological complexity of founder exit events.​​